(Q33362263)

26 July 2017

title

Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery (English)

1 reference

26 July 2017

main subject

venous thromboembolism

1 reference

Antonio Gómez-Outes

2

0 references

author name string

Jesús Honorato

1

1 reference

26 July 2017

Antonio Navarro-Quilis

3

1 reference

26 July 2017

Javier Martínez-González

4

1 reference

26 July 2017

Eduardo Rocha

5

1 reference

26 July 2017

André Planès

6

1 reference

26 July 2017

publication date

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

22

1 reference

26 July 2017

issue

13

1 reference

26 July 2017

page(s)

885-894

1 reference

1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial

26 July 2017

cites work

1 reference

12 December 2020

From the Food and Drug Administration

1 reference

12 December 2020

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis

1 reference

12 December 2020

Recommendations of the Panel on Cost-effectiveness in Health and Medicine

1 reference

12 December 2020

A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group

1 reference

12 December 2020

Review of bemiparin sodium--a new second-generation low molecular weight heparin and its applications in venous thromboembolism

1 reference

12 December 2020

Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial

1 reference

12 December 2020

Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety

1 reference

12 December 2020

Prevention of venous thromboembolism

1 reference

12 December 2020

Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence

1 reference

12 December 2020

Users' guides to the medical literature. XIII. How to use an article on economic analysis of clinical practice. A. Are the results of the study valid? Evidence-Based Medicine Working Group

1 reference

12 December 2020

Low molecular weight heparins: are they interchangeable? No.

1 reference

12 December 2020

FDA public health advisory.

1 reference

12 December 2020

Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.

1 reference

12 December 2020

The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine

1 reference

12 December 2020

10.2165/00019053-200422130-00006

Identifiers

DOI

1 reference

Dimensions Publication ID

26 July 2017

1013226063

0 references

1 reference